Abstract
Influenza A virus poses a direct threat to humans and results in the deaths of about 36,000 people each year in USA. There is tremendous concern that highly virulent variants of the virus may emerge and cause a major pandemic. The influenza virus attacks the respiratory tracts and may cause acute lung inflammation. Certain evidence suggests that the lethal effect of the influenza virus results from inflammation of the host lung rather than from direct viral cytopathy. This has led to the concept that co-administration of effective antiviral agents with inflammation attenuators, by which a reduction, but not an elimination of inflammation would improve lung function without compromising virus clearance, and might result in a better treatment outcome of virulent influenza. Anti-inflammatory antibodies are widely developed for treatment of inflammatory diseases such as Crohns disease, ulcerative colitis, rheumatoid arthritis, psoriasis and so on. This review focuses on anti-inflammatory antibodies and discusses the feasibility and prospects for using them to attenuate the host inflammatory responses in the lung for the treatment and disease management of virulent influenza.
Keywords: Anti-inflammatory antibodies, inflammation attenuators, influenza A virus, treatment and disease management of virulent influenza
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Feasibility and Prospects for Anti-Inflammatory Antibodies in the Treatment and Disease Management of Influenza
Volume: 7 Issue: 2
Author(s): Wei-Gang Hu and Jonathan P. Wong
Affiliation:
Keywords: Anti-inflammatory antibodies, inflammation attenuators, influenza A virus, treatment and disease management of virulent influenza
Abstract: Influenza A virus poses a direct threat to humans and results in the deaths of about 36,000 people each year in USA. There is tremendous concern that highly virulent variants of the virus may emerge and cause a major pandemic. The influenza virus attacks the respiratory tracts and may cause acute lung inflammation. Certain evidence suggests that the lethal effect of the influenza virus results from inflammation of the host lung rather than from direct viral cytopathy. This has led to the concept that co-administration of effective antiviral agents with inflammation attenuators, by which a reduction, but not an elimination of inflammation would improve lung function without compromising virus clearance, and might result in a better treatment outcome of virulent influenza. Anti-inflammatory antibodies are widely developed for treatment of inflammatory diseases such as Crohns disease, ulcerative colitis, rheumatoid arthritis, psoriasis and so on. This review focuses on anti-inflammatory antibodies and discusses the feasibility and prospects for using them to attenuate the host inflammatory responses in the lung for the treatment and disease management of virulent influenza.
Export Options
About this article
Cite this article as:
Hu Wei-Gang and Wong P. Jonathan, Feasibility and Prospects for Anti-Inflammatory Antibodies in the Treatment and Disease Management of Influenza, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2008; 7 (2) . https://dx.doi.org/10.2174/187152308784533212
DOI https://dx.doi.org/10.2174/187152308784533212 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development of Small Molecule Non-peptide Formyl Peptide Receptor (FPR) Ligands and Molecular Modeling of Their Recognition
Current Medicinal Chemistry Primary and Secondary Insomnia: Prevalence, Causes and Current Therapeutics
Current Medicinal Chemistry - Central Nervous System Agents DNMT3B Promoter Polymorphisms and Risk of Late Onset Alzheimer’s Disease
Current Alzheimer Research Methylenetetrahydrofolate Reductase (MTHFR): A Novel Target for Cancer Therapy
Current Pharmaceutical Design Dietary Supplement Therapies for Inflammatory Bowel Disease: Crohn’s Disease and Ulcerative Colitis
Current Pharmaceutical Design Uveitis in Horses, Rats and Man: What Do We Learn from Our Pets?
Current Immunology Reviews (Discontinued) Enhancement of Dissolution Profile of Poorly Water Soluble Drugs by Using Techniques of Nanocrystallization
Current Nanomedicine Th17 and Treg Cells, Two New Lymphocyte Subpopulations with a Key Role in the Immune Response Against Infection
Infectious Disorders - Drug Targets Role of Resistin in Insulin Sensitivity in Rodents and Humans
Current Protein & Peptide Science Cysteine-Rich Mini-Proteins in Human Biology
Current Topics in Medicinal Chemistry Advancement of Mechanisms of Coxsackie Virus B3-Induced Myocarditis Pathogenesis and the Potential Therapeutic Targets
Current Drug Targets Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Role of Inflammatory Mediators in Angiogenesis
Current Drug Targets - Inflammation & Allergy Interleukin-10: An Important Immunoregulatory Cytokine With Major Impact on Psoriasis
Current Drug Targets - Inflammation & Allergy Drug-Induced Aseptic Meningitis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Antioxidant Properties of Crocus Sativus L. and Its Constituents and Relevance to Neurodegenerative Diseases; Focus on Alzheimer’s and Parkinson’s Disease
Current Neuropharmacology Natural Inhibitors against Potential Targets of Cyclooxygenase, Lipoxygenase and Leukotrienes
Combinatorial Chemistry & High Throughput Screening Current Treatments of Primary Sclerosing Cholangitis
Current Medicinal Chemistry The IL23/Th17 Pathway as a Therapeutic Target in Chronic Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Effects of Chrisotherapeutic Gold Compounds on Prostaglandin E2 Production
Current Drug Targets - Inflammation & Allergy